Lead Targeted Therapeutic
TransCode’s scientific co-founders discovered that metastatic tumor cells cannot survive without the overexpression of a specific non-coding RNA molecule, microRNA-10b, which regulates the viability of metastatic tumor cells.
Against this conceptual framework, TransCode has designed the first known cancer therapeutic, TTX-MC138, that efficiently inhibits microRNA-10b in metastatic tumor cells, resulting in the complete regression of established metastases with no recurrence and no toxicity. The patented technology representing microRNA-10b therapeutics, and a companion biomarker test for non-invasive detection of microRNA activity, is licensed from Massachusetts General Hospital.
INHIBITING microRNA-10b WITH TTX-MC138
- TransCode’s initial target, microRNA-10b, is the master regulator for the survival of metastatic tumor cells
- Inhibition of microRNA-10b leads to metastatic tumor cell death
- TransCode has created a platform of targeted therapeutics addressing multiple metastatic tumor types